Fractional CFO for Biotech: Runway, Fundraising, and Trial Costs in a Tighter 2026 Market
November 18, 20267 min read
A biotech company with eighteen months of cash and a Phase 1 readout next spring doesn't have a finance problem, exactly. It has a runway problem, a fundraising problem, and a board that wants to know which programs to cut if the data disappoints. A fractional CFO for biotech exists for that moment: senior finance leadership tied to scientific milestones, at a cost a pre-revenue company can justify.
Demand for that kind of help is rising because the money is getting harder to land. Capital is flowing into the sector, but it's going to fewer companies, and investors expect clean books and credible forecasts before they write a check.
Why biotech funding makes the CFO seat matter more in 2026
On the surface, 2026 looks like a decent year for biotech funding. J.P. Morgan's Q3 2026 Biopharma Licensing and Venture Report counts $23.9 billion in biopharma venture funding across 385 rounds through September, and the year is on pace to beat 2025. But the quarter-to-quarter picture is choppier. Q3 brought in $6.7 billion, down from $9.9 billion in Q2.
The distribution matters more than the total. BioCentury's first-half analysis found that biotech drew more venture dollars while deal count stayed lean: 366 financings, near the lowest first-half count in a decade, with 14 megarounds taking almost a third of the capital. More money is going into fewer, bigger bets.
For an early-stage company, that means the bar is higher. Investors spend longer in diligence and expect monthly GAAP financials, a detailed forecast, and documented controls, a point the CPA firm AAFCPAs makes in its guide to funding in a more selective life sciences market. A company that walks in with a messy model is easy to pass on.
What a fractional CFO for biotech actually does
Biotech finance doesn't look like SaaS finance. There's usually no revenue to forecast, so the whole model hangs on cash burn, program timelines, and the next value-inflection point. The work tends to fall into a few areas.
Runway and scenario planning is the core. A good biotech CFO builds a milestone-based model that shows how long cash lasts under different trial outcomes, and which programs or hires get paused if a readout slips. Boards want to see that tradeoff laid out before they need to make it.
Fundraising readiness comes next. That means the data room, the financial sections of the pitch, valuation context, and a clear use-of-proceeds story tied to milestones. Our guide to using a fractional CFO for fundraising covers the general playbook. Biotech adds a layer of scientific diligence that the CFO has to translate into dollars and months.
Trial and CRO cost management is where biotech-specific experience pays for itself. Clinical trials run through contract research organizations with complex budgets, pass-through costs, and change orders. A CFO who has managed CRO contracts can spot overruns early and set up accrual processes that hold up in an audit.
Then there's the compliance work that rarely gets attention until it's urgent: R&D tax credit documentation, grant accounting for NIH or SBIR funding, equity administration, and audit preparation ahead of a larger round or an IPO.
When a biotech should hire fractional instead of full-time
Most seed and Series A biotechs don't need a full-time CFO. The finance workload comes in bursts: heavy around a raise, a board meeting, or a year-end audit, and quieter in between. Paying a full-time executive salary plus equity through the quiet months is a hard sell when every dollar of runway is measured against lab time.
The fractional model fits a few situations especially well:
- A company preparing for its first institutional round that has outgrown a founder-built spreadsheet
- A grant-funded team moving to venture capital and needing GAAP reporting for the first time
- A company approaching its first clinical trial, when CRO contracts and accruals start to dominate spending
- A board that wants an independent finance voice on runway and program prioritization
- A company bridging the gap while it runs a search for a permanent CFO ahead of a later-stage raise or IPO
The handoff point usually comes around Series B or a late-stage clinical program, when investor reporting, audit requirements, and headcount justify a full-time leader. Many fractional CFOs help recruit and onboard their replacement. If you're weighing the general tradeoff, our comparison of fractional vs. full-time executive cost breaks down the math.
Fractional CFO biotech cost and engagement structure
Biotech engagements usually land at the higher end of fractional finance pricing. The work requires specialized knowledge, the stakes around a raise are high, and the pool of CFOs who have actually closed life sciences rounds is small. Most engagements run as a monthly retainer for a set number of days, with a step-up in hours during fundraising or audit season.
Scope drives price more than title. A CFO who mainly reviews the model and joins board meetings costs far less than one who is running a Series A process, managing the CRO budget, and overseeing a first audit at the same time. For current ranges by engagement type, see our breakdown of fractional CFO cost in 2026.
Two things to clarify early. First, decide whether equity is part of the package. Biotech founders often prefer to conserve cash, and a fractional CFO may accept a smaller retainer plus options. Second, define who does the transactional bookkeeping. A fractional CFO should be setting strategy and controls, not entering invoices, so most companies pair one with an outsourced accounting firm.
What to look for in a fractional biotech finance leader
General CFO experience isn't enough here. The questions that separate a strong candidate are specific: Have they raised money from life sciences investors? Have they managed CRO budgets and clinical accruals? Do they understand how milestone-based financings and tranched rounds work? Can they talk credibly with your chief scientific officer about why a program timeline drives the burn?
Look for someone who has seen at least one full cycle, from a seed round through a clinical readout and the financing that followed. That pattern recognition is what lets them tell a board which costs are fixed and which can flex. Many biotech fractional CFOs also work alongside other part-time scientific leaders. If you're building out a lean senior team, our guide to fractional chief medical officer cost covers the clinical side.
For finance executives with that background, this is a strong niche to build a practice around. Biotech founders are often scientists who know they need help with the money side and are willing to pay for someone who speaks both languages.
Where biotech finance is heading
The funding pattern of 2026, with more dollars concentrated in fewer companies, isn't likely to reverse soon. That puts a premium on companies that can prove capital efficiency early, and on finance leaders who can build the case. For many biotechs, a part-time CFO who has been through it before is the most efficient way to get there.
If you're a finance executive with life sciences experience, now is a good time to make that expertise visible to the founders and boards who are looking for it.
Companies find fractional finance leaders by searching for the specific experience they need. A clear profile that names your sector, stage, and track record makes that search easier. Create your free profile on ExecRoster.
For experienced executives
Get found and hired for fractional work.
- A profile companies can find
- A calendar they can book
- Paid to your bank, you keep 90%
Frequently asked questions
What does a fractional CFO for biotech do day to day?+
A fractional CFO for biotech builds milestone-based runway models, prepares the company for fundraising, and manages clinical trial and CRO costs. The role also covers compliance work such as R&D tax credit documentation, grant accounting for NIH or SBIR funding, equity administration, and audit preparation.
When should a biotech company hire a fractional CFO instead of a full-time one?+
Most seed and Series A biotechs fit the fractional model because finance work comes in bursts around a raise, a board meeting, or a year-end audit. The handoff to a full-time CFO usually comes around Series B or a late-stage clinical program, when investor reporting, audit requirements, and headcount justify it.
How is a fractional CFO for biotech usually paid?+
Most engagements run as a monthly retainer for a set number of days, with more hours during fundraising or audit season. Biotech work tends to land at the higher end of fractional finance pricing, and some CFOs accept a smaller retainer plus options when founders want to conserve cash.
What experience should a biotech finance leader have before you hire them?+
Look for someone who has raised money from life sciences investors, managed CRO budgets and clinical accruals, and understands milestone-based and tranched financings. Ideally they have seen one full cycle, from a seed round through a clinical readout and the financing that followed.